TRAWS PHARMA INC

New 97k stock‑option awards at Traws Pharma signal insider confidence and a push for growth—what this means for investors and future value.

Inside Traws Pharma’s latest option awards, CAUTREELS WERNER’s incremental buys signal insider optimism—will a drug breakthrough lift the stock?

TRAWS Pharma insider buy: COO Savchuk adds 93k stock options, signaling long‑term confidence while market sentiment remains cautious and upside depends on future drug approvals.

Insider STOVER JACK E buys Traws Pharma options, signaling confidence in the company’s pivot to antiviral therapeutics and potential future upside.

Insider buying of Traws Pharma options shows executive confidence in its new respiratory‑therapeutics push—watch FDA milestones for upside.

Strategic insider stock‑option awards at Traws Pharma signal executive confidence—potential future rally if clinical milestones hit, boosting long‑term investor upside.